

Special Issue

Tumor Innate Immune Surveillance

Message from the Guest Editor

Key immune evasion mechanisms in established tumors have been well characterized, culminating with the clinical approval of several drugs targeting T cell immune checkpoints (ICP). By contrast, while the concept of tumor immune surveillance is well accepted, the very early events that permit immune sensing of pre-neoplastic cells remain poorly understood. The objective of this Special Issue is to gather original studies and reviews addressing immune sensing mechanisms of early cell transformation. The Special Issue is expected to assemble studies analyzing interactions between cells undergoing transformation and innate immune cells based on in vitro and/or in vivo models. Studies on conventional T/B cells are out of the scope of this Special Issue. Of specific interest are studies deciphering the role in the detection of early cell transformation of specific immune cell types, such as dendritic cells, macrophages, neutrophils, and other myeloid cells, and of innate lymphoid cells, including unconventional T cells (NKT, gdT cells) and NK cells.

Guest Editor

Dr. Christophe Caux

Cancer Research Center Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon, France

Deadline for manuscript submissions

closed (31 January 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/37033

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)